Hutchmed (China) Limited
HCM
ISIN US44842L1035 / Valor 30165904
Hutchmed (China) Limited
UMushroom community rating:
About company
Hutchmed (China) Limited is a biopharmaceutical company that focuses on research and development in the areas of cancer and immunological diseases. The company's core philosophy involves utilizing multiple modalities and mechanisms to develop highly selective, potent, and well-tolerated cancer therapies. Hutchmed is dedicated to improving drug exposure and reducing off-target toxicities through a science-focused approach.
Summarized from source with an LLMView SourceSector: HealthcareLatest Results (07.08.2024):
Revenue Growth
Hutchmed (China) Limited reported a consolidated oncology product revenue of $168.7 million for the first half of 2024, driven by a 59% growth in oncology product revenue compared to the same period in 2023. This growth was primarily fueled by the strong performance of their oncology products in the market.
FRUZAQLA® Sales
FRUZAQLA® (fruquintinib ex-China) achieved US in-market sales of $130.5 million in the first half of 2024. This strong performance reflects the rapid uptake by US patients and the fulfillment of sales channel inventory requirements since its launch in November 2023.
Net Income
Hutchmed (China) Limited reported a net income of $25.8 million for the first half of 2024. This positive financial result underscores the company's ability to generate profit while continuing to invest in key R&D projects and enhancing commercial efficiency.
Cash Balance
As of June 30, 2024, Hutchmed (China) Limited maintained a substantial cash balance of $802.5 million. This strong cash position supports the company's ongoing growth initiatives and strategic investments in research and development.
Oncology In-Market Sales
Oncology in-market sales for Hutchmed (China) Limited increased by 140% to $243.3 million in the first half of 2024, compared to $101.3 million in the same period of 2023. This significant growth was driven by the strong performance of key products such as FRUZAQLA®, ELUNATE®, SULANDA®, and ORPATHYS®.
Summarized from source with an LLMView SourceKey figures
Performance
Volatility
2955 M
Market cap (USD)
37,026
Daily traded volume (Shares)
17.12 / 16.48
1 day high/low (USD)
52 weeks high/low (USD)
Dividend ex-date
Dividend (USD)
Dividend yield (p.a.)
Est dividend (USD)
Est dividend yield
P/E ratio
Est P/E ratio
EPS (USD)
Est EPS (USD)
Ratings & reviews
EQUITIES OF THE SAME SECTOR
